Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Camp4 Therapeutics (CAMP) Net Income towards Common Stockholders: 2023-2025

Historic Net Income towards Common Stockholders for Camp4 Therapeutics (CAMP) over the last 2 years, with Sep 2025 value amounting to -$13.2 million.

  • Camp4 Therapeutics' Net Income towards Common Stockholders rose 1.90% to -$13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$51.6 million, marking a year-over-year decrease of 0.41%. This contributed to the annual value of -$51.8 million for FY2024, which is 5.07% down from last year.
  • Per Camp4 Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$13.2 million for Q3 2025, which was down 5.19% from -$12.6 million recorded in Q2 2025.
  • In the past 5 years, Camp4 Therapeutics' Net Income towards Common Stockholders ranged from a high of -$11.7 million in Q3 2023 and a low of -$13.5 million during Q3 2024.
  • Its 3-year average for Net Income towards Common Stockholders is -$12.7 million, with a median of -$12.6 million in 2025.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first fell by 15.29% in 2024, then increased by 1.90% in 2025.
  • Camp4 Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$13.0 million in 2023, then dropped by 2.22% to -$13.3 million in 2024, then climbed by 1.90% to -$13.2 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$13.2 million for Q3 2025, versus -$12.6 million for Q2 2025 and -$12.5 million for Q1 2025.